Search Results
Your search for ,twO matches 12333 pages
Showing 5301 - 5350PIK3CA Mutation Status and Disease-Free Survival in Patients With HPV-Associated Head and Neck Cancer Treated With Deintensified Chemoradiotherapy
In a study reported in the Journal of the National Cancer Institute, Beaty et al found that the presence of a PIK3CA mutation was associated with poorer disease-free survival among patients receiving deintensified definitive chemoradiotherapy for human papillomavirus (HPV)-associated oropharyngeal...
DUOX2 Mutation in Familial Thyroid Cancers
Researchers have identified a new genetic mutation that may cause a type of familial thyroid cancer. According to the researchers, DUOX2 is the first and only mutation associated with familial thyroid cancer to be identified in a gene that is primarily expressed in the thyroid gland. These findings ...
Reports From the ESMO Asia Congress 2019
This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We’ll also discuss last week’s FDA approval of acalabrutinib for chronic...
FDA Pipeline: Recent Designations in Hepatocellular Carcinoma, Cholangiocarcioma, Lymphoma, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) granted reviews or designations to treatments for gastrointestinal cancers and lymphoma, and also provided authorizations for products designed to screen for malignancies and tumor mutational burden. Priority Review for Nivolumab...
Activity of Anti-STEAP1 Antibody-Drug Conjugate in Patients With Metastatic Castration-Resistant Prostate Cancer
In a phase I trial reported in the Journal of Clinical Oncology, Danila et al found that the antibody-drug conjugate DSTP3086S, which targets the six-transmembrane epithelial antigen of the prostate 1 (STEAP1), had acceptable safety and evidence of activity in patients with metastatic...
ICARIA-MM: Addition of Isatuximab to Pomalidomide/Dexamethasone in Relapsed and Refractory Multiple Myeloma
As reported in The Lancet by Michel Attal, MD, and colleagues, the phase III ICARIA-MM trial has shown that the addition of the CD38-targeted antibody isatuximab to pomalidomide and low-dose dexamethasone significantly improved progression-free survival in patients with relapsed and refractory...
ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported by Xu et al at the European...
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma
More than one out of two patients with metastatic melanoma treated with the combination of nivolumab plus ipilimu-mab is still alive after 5 years, according to the longest follow-up of patients receiving this combination. In two additional studies, the immunotherapy duet also proved to be active...
2020 ASCO Election Candidates
The ASCO Nominating Committee has selected 14 ASCO members as candidates for open leadership positions within the Society, including: The office of President-Elect Four seats on the Board of Directors Two seats on the Nominating Committee. All eligible ASCO members* can vote, and the voting...
ASCO President-Elect Candidates Discuss Key Issues in Oncology
Patrick J. Loehrer, MD, FASCO, of the Indiana University Melvin and Bren Simon Cancer Center, and Everett E. Vokes, MD, FASCO, of the University of Chicago Medicine Comprehensive Cancer Center, were selected by the ASCO Nominating Committee as candidates for President-Elect. Below, they discuss...
National Academy of Medicine Elects New Members, Including Many From Oncology Community
The National Academy of Medicine has announced the election of 90 regular members and 10 international members during its Annual Meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding ...
Using the Nobel Prize to Champion Curiosity-Driven Research in Cancer
William G. Kaelin, Jr, MD, Sidney Farber Professor of Medicine and Howard Hughes Medical Institute Investigator at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, admits that early in his research career, he and his late wife, Carolyn, would have fun...
When to Consider Local Therapy for Stage IV Breast Cancer
Local therapy for stage IV breast cancer has not been proven to increase overall survival, yet there are some cases where local therapy could be considered outside a clinical trial. For patients with intact asymptomatic primary tumors, local therapy could be offered if distant disease is well...
Oncology Clinicians Play A Role in Telling Patients About the Importance of Exercise
New exercise guidelines for patients with cancer can “improve physical and psychological outcomes from cancer diagnosis and for the balance of life,” concluded representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control.1 Attention...
A Call to Action for Oncology Clinicians to Help Patients ‘Move Through Cancer’
“There is clear evidence that patients are more likely to exercise if their oncologist tells them to do so,” reported representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control. In an article published in CA: A Cancer Journal for...
University of Michigan Cancer Programs Receive $9.2M Grant for Prostate Cancer Research
Two Michigan cancer programs are joining forces to find new solutions for prostate cancer. The University of Michigan (U-M) Rogel Cancer Center and the Barbara Ann Karmanos Cancer Institute at Wayne State University have received a $9.2 million grant from the National Cancer Institute (NCI). The...
Past President of ASH, Stanford Professor, Stanley L. Schrier, MD, Dies at 90
Stanley L. Schrier, MD, Past President of the American Society of Hematology (ASH, 2004–2005) and Professor Emeritus of Hematology at Stanford Medicine in Palo Alto, died on August 16. He was 90 years old. Instrumental to Growth at Stanford Dr. Schrier was a 1954 graduate of Johns Hopkins...
Calaspargase Pegol-mknl for Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia
In late 2018, calaspargase pegol-mknl, an asparagine-specific enzyme, was approved for use as a component of a multiagent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years.1,2 The new product provides for a longer interval ...
Clinical Happenings and Highlights at the 2019 ASH Annual Meeting
The 61st American Society of Hematology (ASH) Annual Meeting & Exposition is being held December 7–10, 2019, at the Orange County Convention Center in Orlando. Be sure to visit The ASCO Post in the exhibit hall (booth 2429, Harborside) and watch interviews with experts being filmed there live....
Trifluridine/Tipiracil in Recurrent, Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Early in 2019, trifluridine/tipiracil tablets were approved for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine; a platinum; either a taxane or...
Analysis of 4-Year Survival With Nivolumab in Patients Previously Treated for Advanced NSCLC
In an analysis reported in The Lancet Oncology, Scott J. Antonia, MD, PhD, of Duke Cancer Institute, and colleagues identified long-term survival rates with nivolumab therapy in patients with previously treated advanced non–small cell lung cancer (NSCLC), including comparative outcomes vs...
Oncology Massage Therapy for Chemotherapy-Induced Peripheral Neuropathy
Oncology massage therapy might be a helping hand for patients suffering from chronic chemotherapy-induced peripheral neuropathy, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of the pilot study supported the premise that patients who received massages...
Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC
In patients with stage IV squamous non–small cell lung cancer (NSCLC), those with high programmed cell death ligand 1 (PD-L1) expression treated with atezolizumab and chemotherapy experienced longer overall survival rates than those treated with chemotherapy alone. For those participants without...
First-Line Nivolumab Plus Ipilimumab in Special Populations With Non–Small Cell Lung Cancer
First-line therapy consisting of nivolumab plus ipilimumab showed a consistent safety profile in special populations with advanced non–small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung ...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
Elotuzumab in Combination Therapy for Previously Treated Multiple Myeloma
In late 2018, elotuzumab was approved for use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.1 Supporting Efficacy Data Approval was based ...
Study Finds Durvalumab Retreatment Active in Some Patients With Advanced Solid Tumors
Immunotherapy with checkpoint inhibitors offers a proportion of patients a chance at long-term disease control, resembling cure in some patients. Among the many questions about immunotherapy that remain to be resolved is whether patients who discontinue therapy and develop progressive disease can...
Navneet S. Majhail, MD, MS, Was Inspired by His Father’s Career as a Military Doctor and His Mother’s Battle With Cancer
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Navneet S. Majhail, MD, MS, about his journey from India to the Cleveland Clinic, where he is Director of the Blood and Marrow Transplant Program. He is also President of the American Society for...
Addressing the Obesity Epidemic and Barriers to Implementing Weight Management Programs for Cancer Survivors
Earlier this year, ASCO published the results of its new study on oncologists’ perceptions and practice behaviors regarding obesity, weight management, and related lifestyle factors in their patients both during and after cancer treatment.1 The findings from the online survey of 971 oncology...
Nivolumab vs Chemotherapy in Advanced Esophageal Cancer
Nivolumab improved overall survival compared with chemotherapy in previously treated patients with esophageal squamous cell carcinoma in the final analysis of the phase III ATTRACTION-3 study. The data were presented at the European Society for Medical Oncology (ESMO) Congress 2019 Presidential...
FDA Office of Hematology Oncology Products Reorganized, Renamed Office of Oncologic Diseases
As part of modernization plans approved in September 2019, the U.S. Food and Drug Administration (FDA) office responsible for reviewing applications for new and existing cancer therapies has reorganized and been renamed. The Center for Drug Evaluation and Research (CDER) Office of Hematology and...
Award Winners Named for 2019 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) will honor two renowned researchers for their work in breast cancer at the 2019 SABCS, to be held December 10–14 in San Antonio. Myles Brown, MD, is the recipient of the 2019 AACR Distinguished ...
Expert Point of View: Arndt Vogel, MD and Angela Lamarca, MD, PhD
Arndt Vogel, MD, of Hannover Medical School in Germany, who served as discussant of the two studies of immunotherapy in hepatocellular carcinoma, said the findings point to a promising future in the treatment of this malignancy. He commented that the responses observed with nivolumab in CheckMate...
‘Clinically Meaningful’ Outcomes Seen in Two Studies of First-Line Immunotherapy for Hepatocellular Carcinoma
In the first-line treatment of advanced hepatocellular carcinoma, checkpoint inhibitors led to favorable outcomes in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019—though one study was technically negative. The current first-line standard of care for unresectable ...
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
On September 17, 2019, apalutamide was approved for the treatment of patients with metastatic castration-sensitive prostate cancer.1,2 Supporting Efficacy Data The approval is based on overall survival and radiographic progression-free survival findings in the phase III double-blind TITAN trial.2,3 ...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
City of Hope’s Michael Caligiuri, MD, Formally Appointed to Deana and Stave Campbell Physician-in-Chief Distinguished Chair
Michael A. Caligiuri, MD, President of City of Hope National Medical Center, in Duarte, California, has been appointed the Deana and Steve Campbell Physician-in-Chief Distinguished Chair in Honor of Alexandra Levine, MD. The position was created in honor of Dr. Levine, a City of Hope Professor of...
Circulating Tumor DNA: A Prognostic Marker in Stage III Colon Cancer?
Circulating tumor DNA in the blood could serve as a marker of prognosis in patients with colon cancer receiving adjuvant oxaliplatin, according to a subanalysis of the IDEA trial, presented at the European Society for Medical Oncology (ESMO) Congress 2019.1 After 2 years of adjuvant...
Breast Cancer Treatments Targeting Estrogen May Be Putting Patients at Risk for Long-Term Comorbidities
“The majority of breast cancers are hormone receptor–positive, and treatments that target the estrogen receptors are very effective, but they also cause havoc in many tissues that are dependent on estrogen for normal functioning. As a result, breast cancer survivors suffer from ongoing symptoms and ...
Selinexor/Dexamethasone in Refractory Multiple Myeloma: The STORM Has Arrived, but Does It Represent Climate Change?
The term “relapsed/refractory multiple myeloma” is often used to describe advanced myeloma that has progressed through primary or salvage therapy. The International Myeloma Working Group (IMWG) defined the term in 2011 as disease that is “nonresponsive while on salvage therapy or progresses...
ASCO Updates Breast Cancer Risk Reduction Guideline to Include Anastrozole
ASCO has updated a guideline on pharmacologic interventions for breast cancer risk reduction in postmenopausal women at increased risk of developing breast cancer.1 The original clinical practice recommendations for breast cancer risk reduction were published in 1999 and updated in 2002, 2009, and...
Challenging the Global Community to Deliver Equitable Cancer Care for All
For Her Royal Highness Princess Dina Mired of Jordan, ensuring that every patient with cancer receives high-quality care is not an abstract goal—it is personal. Princess Dina saw firsthand the life-and-death differences that access to state-of-the-art oncology care makes in a patient’s life when...
Answers to Hematology Expert Review Questions
Question 1 Which of the following statements about cytokine-release syndrome and neurotoxicity after tisagenlecleucel infusion is correct? Correct answer: B. The median time to onset of cytokine-release syndrome is 3 days. Expert Perspective Following tisagenlecleucel infusion, cytokine-release...
CAR T-Cell Gene Therapy: Toxicities and Management Principles
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” —Marie Curie The ASCO Post is pleased to present Hematology ...
Project Socrates: An Educational Bridge From the FDA to the Public
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Jennifer J. Gao, MD, Acting Associate Director of Education in the OCE, and Richard Pazdur, MD, Director of ...
Glasdegib in Older Patients With AML or Those With Comorbidities
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Late in 2018, the Hedgehog pathway inhibitor glasdegib...
Nivolumab/Ipilimumab: Another First-Line Option for Advanced NSCLC
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
Mental Health Outcomes in Mothers and Siblings of Children With Cancer
In a Canadian study reported in the Journal of Clinical Oncology, van Warmerdam et al found that mothers and siblings of children with cancer were significantly more likely to have mental health–related outpatient health-care contacts than their general population counterparts. The study involved...
Machine Learning Algorithm for Genome-Derived Prediction of Tumor Type
In a study reported in JAMA Oncology, Penson et al developed a machine learning algorithmic classifier that may be successful in identifying tumor type and origin based on DNA-sequence data obtained at point of care. The study used machine learning to construct and train an algorithmic classifier...
Characteristics of Metastatic Lesion Responses to PD-1 Inhibition
In a study reported in the Journal of Clinical Oncology, Osorio et al found that responses to programmed cell death protein 1 (PD-1) inhibitor therapy tended to be consistent across metastases and occur simultaneously in metastatic lesions of non–small cell lung cancer (NSCLC) and mismatch...
